https://www.prnewswire.com/news-releases/kalivir-immunotherapeutics-and-astellas-enter-worldwide-exclusive-licensing-agreement-for-development-and-commercialization-of-vet2-l2-novel-oncolytic-virus-301186994.html
/PRNewswire/ -- KaliVir Immunotherapeutics LLC (CEO: Helena Chaye, Ph.D., J.D., "KaliVir") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...
licensing agreementimmunotherapeuticsastellasenterworldwide
https://pubmed.ncbi.nlm.nih.gov/28271869/
Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a...
guidelinesresponsecriteriausetrials
https://stockhouse.com/companies/financials?symbol=scni
Financial Review of Scinai Immunotherapeutics Ltd (NDAQ:SCNI). Includes Income Statement, Balance Sheet, and Cash Flow across multiple years and reporting...
ndaqfinancialsimmunotherapeuticsltd
https://www.cnrsinnovation.com/actualite/ose-immunotherapeutics-derniere-ligne-droite-pour-ce-vaccin-contre-le-cancer-du-poumon/
Les résultats de l’essai clinique de phase 3 du vaccin thérapeutique Tedopi consacrent les travaux de cette PME française, cofondée par une directrice de...
cnrsinnovationraquoimmunotherapeuticsligne